TheraNovis

History

Building validated technology toward platform commercialization

2021
  • TheraNovis Co., Ltd. Established

  • MOU Signed with BioActs and Six Additional Organizations

  • Established Corporate R&D Centers (Hanam / Yangsan)

2022
  • Executing the Regional Specialized Industry Development Program (MSS)

  • Selected for PNU Yangsan Bio Core Facility Program (KRW 600M / 3 years)

  • Selected for the KIBO Tech-Bridge Program

  • Selected for the Asan Medical Center Incentive Program

2023
  • Secured KRW 300M in TIPS funding

  • Secured KRW 336M in strategic (SI) investment

  • Selected for MSS Deep-Tech TIPS Program (KRW 1.5B / 3 years)

  • Selected for Seoul-type TIPS Program (KRW 400M / 2 years)

  • Selected for Medical Device Industry Transition Infrastructure Program

  • Launch of Phenoview (now AstraTSA)

2024
  • MOU signed with AtheonBio

  • MOU signed with Intec Scientific

  • Selected for MOTIE Materials & Components Technology Development Program (KRW 10B / 5 years)

  • Initiated establishment of Boston, USA liaison office

  • Secured KRW 1B in strategic (SI) investment from IntekPlus

  • Launch of Skin GeneCurator skin condition assessment service

2025
  • Launch of semi-automated staining system

  • Secured KRW 220M in funding from a private investment fund

Tap an item to highlight it.